Related Experiment Videos
CAG trinucleotide RNA repeats interact with RNA-binding proteins
B A McLaughlin1, C Spencer, J Eberwine
1Institute of Neurological Sciences, University of Pennsylvania, Philadelphia, USA.
American Journal of Human Genetics
|September 1, 1996
Summary
Researchers found that specific RNA-binding proteins interact with CAG repeat sequences in the brain. These interactions, crucial for understanding trinucleotide repeat diseases like Huntington's disease, are dependent on repeat length.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Trinucleotide repeat sequences, particularly expanded CAG repeats, are linked to neurological disorders such as Huntington's disease (HD).
- The exact mechanisms by which these expanded repeats cause neuronal degeneration remain largely unknown.
- RNA-binding proteins are known to influence gene expression in eukaryotes.
Purpose of the Study:
- To investigate the association between cytoplasmic proteins and normal versus expanded CAG repeat sequences.
- To identify potential RNA-binding proteins involved in the pathology of trinucleotide repeat-associated neurological diseases.
Main Methods:
- Gel shift assays were employed to detect protein-RNA interactions.
- UV crosslinking assays were used to confirm the binding of cytoplasmic proteins to CAG repeats.
- Protein extracts from rat and human brain regions (striatum, cortex) were analyzed.
Main Results:
- A 63-kD RNA-binding protein in rat brain extracts specifically interacts with CAG repeat sequences.
- The binding affinity of this protein is dependent on the length of the CAG repeat, with longer repeats showing stronger binding.
- Two CAG repeat-binding proteins (63 kD and 49 kD) were identified in human brain extracts.
Conclusions:
- Cytoplasmic RNA-binding proteins associate with both normal and expanded CAG repeats.
- These protein-RNA interactions may play a significant role in the pathogenesis of neurological diseases caused by trinucleotide repeat expansions.
- The findings suggest novel therapeutic targets for trinucleotide repeat disorders.